| Jamil Khatri, MD | |
|
4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 | |
| (302) 731-7782 | |
| (302) 738-5917 |
| Full Name | Jamil Khatri |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 35 Years |
| Location | 4701 Ogletown Stanton Rd, Newark, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427008622 | NPI | - | NPPES |
| 731500701 | Medicaid | MD | |
| 0001111201 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | C10006241 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Union Hospital Of Cecil County | Elkton, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
Autism is a neurological and developmental diagnosis seen from early childhood marked by difficulty in communicating, forming relationships and using languages.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Milestone Scientific Inc., the recognized leader in advanced, computer-controlled drug delivery technologies, announces its financial results for the third quarter and nine months ended September 30, 2010.
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose.
› Verified 2 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
Autism is a neurological and developmental diagnosis seen from early childhood marked by difficulty in communicating, forming relationships and using languages.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Milestone Scientific Inc., the recognized leader in advanced, computer-controlled drug delivery technologies, announces its financial results for the third quarter and nine months ended September 30, 2010.
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose.
› Verified 2 days ago
| Entity Name | Regional Hematology And Oncology P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811947054 PECOS PAC ID: 0749175586 Enrollment ID: O20070521000381 |
News Archive
Autism is a neurological and developmental diagnosis seen from early childhood marked by difficulty in communicating, forming relationships and using languages.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Milestone Scientific Inc., the recognized leader in advanced, computer-controlled drug delivery technologies, announces its financial results for the third quarter and nine months ended September 30, 2010.
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamil Khatri, MD 4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 Ph: (302) 731-7782 | Jamil Khatri, MD 4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 Ph: (302) 731-7782 |
News Archive
Autism is a neurological and developmental diagnosis seen from early childhood marked by difficulty in communicating, forming relationships and using languages.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Milestone Scientific Inc., the recognized leader in advanced, computer-controlled drug delivery technologies, announces its financial results for the third quarter and nine months ended September 30, 2010.
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose.
› Verified 2 days ago
Shruti Puri, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 Fax: 302-733-5640 | |
Zaid A Ammari, M.D. M.P.H. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1000 Fax: 347-851-8707 | |
Dr. Suresh Trivedi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 111 Continental Dr, Suite 406, Newark, DE 19713 Phone: 302-368-2630 Fax: 302-368-1271 | |
Dr. Bradley Bley, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1096 Old Churchmans Rd, Newark, DE 19713 Phone: 302-655-9494 Fax: 302-351-4898 | |
Dr. Avinash Chandra, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 86 Omega Dr, Omega Professional Center, Building B-86, Newark, DE 19713 Phone: 302-366-1929 Fax: 302-366-1006 | |
Dr. Lucinda Li, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 | |
Dr. James Robinson Mcninch Iv, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1148 |